CN1304005C - 受体酪氨酸激酶抑制剂和α1－酸性糖蛋白结合化合物的联合形式 - Google Patents

受体酪氨酸激酶抑制剂和α1－酸性糖蛋白结合化合物的联合形式 Download PDF

Info

Publication number
CN1304005C
CN1304005C CNB008178976A CN00817897A CN1304005C CN 1304005 C CN1304005 C CN 1304005C CN B008178976 A CNB008178976 A CN B008178976A CN 00817897 A CN00817897 A CN 00817897A CN 1304005 C CN1304005 C CN 1304005C
Authority
CN
China
Prior art keywords
sti571
abl
tyrosine kinase
agp
pdgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008178976A
Other languages
English (en)
Chinese (zh)
Other versions
CN1414858A (zh
Inventor
C·甘巴科尔蒂－帕塞里尼
P·勒库特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1414858A publication Critical patent/CN1414858A/zh
Application granted granted Critical
Publication of CN1304005C publication Critical patent/CN1304005C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNB008178976A 1999-12-27 2000-12-22 受体酪氨酸激酶抑制剂和α1－酸性糖蛋白结合化合物的联合形式 Expired - Fee Related CN1304005C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI99A002711 1999-12-27
IT1999MI002711A ITMI992711A1 (it) 1999-12-27 1999-12-27 Composti organici

Publications (2)

Publication Number Publication Date
CN1414858A CN1414858A (zh) 2003-04-30
CN1304005C true CN1304005C (zh) 2007-03-14

Family

ID=11384195

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008178976A Expired - Fee Related CN1304005C (zh) 1999-12-27 2000-12-22 受体酪氨酸激酶抑制剂和α1－酸性糖蛋白结合化合物的联合形式

Country Status (18)

Country Link
US (2) US20030125343A1 (enExample)
EP (1) EP1250140B1 (enExample)
JP (1) JP2003523325A (enExample)
CN (1) CN1304005C (enExample)
AR (1) AR030179A1 (enExample)
AT (1) ATE432069T1 (enExample)
AU (1) AU2171901A (enExample)
BR (1) BR0016817A (enExample)
CA (1) CA2394944A1 (enExample)
CO (1) CO5271710A1 (enExample)
DE (1) DE60042283D1 (enExample)
ES (1) ES2326307T3 (enExample)
HK (1) HK1050993A1 (enExample)
IT (1) ITMI992711A1 (enExample)
PE (1) PE20010991A1 (enExample)
PT (1) PT1250140E (enExample)
TW (1) TWI246917B (enExample)
WO (1) WO2001047507A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2290199T3 (es) * 2000-11-22 2008-02-16 Novartis Ag Mezcla que incluye un agente que reduce la actividad de fcve y un agente que reduce la actividad de fce.
WO2003000186A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel phenylamino-pyrimidines and uses thereof
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US7323469B2 (en) 2001-08-07 2008-01-29 Novartis Ag 7H-pyrrolo[2,3-d]pyrimidine derivatives
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
DK1441714T3 (da) * 2001-10-25 2008-03-31 Novartis Ag Kombinationer omfattende en selektiv cyclooxygenase-2-inhibitor
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
WO2003080061A1 (en) * 2002-03-21 2003-10-02 Dana-Farber Cancer Institute, Inc. Inhibition of cell death responses induced by oxidative stress
AU2007201830C1 (en) * 2002-04-23 2017-09-07 Novartis Pharma Ag High drug load tablet
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
AU2003295320A1 (en) * 2002-06-26 2004-04-08 The Ohio State University Research Foundation The method for reducing inflammation using sti-571 or its salt
AU2003232376A1 (en) * 2002-07-24 2004-02-09 Novartis Ag 4-(4-methylpiperazin-1-ylmethyl)-n-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating anaplastic thyroid cancer
CA2494061C (en) * 2002-07-31 2011-06-14 Wayne R. Danter Protein tyrosine kinase inhibitors
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
WO2004033446A1 (en) * 2002-10-09 2004-04-22 Danter Wayne R Protein tyrosine kinase inhibitors
WO2005027910A1 (en) * 2003-08-25 2005-03-31 Dana-Farber Cancer Institute Inc. Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias
US20080096864A1 (en) * 2003-09-19 2008-04-24 Sasa Dimitrijevic Treatment Of Gastrointestinal Stromal Tumors With Imatinib And Midostaurin
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
CA2555804C (en) † 2004-02-11 2012-06-26 Natco Pharma Limited Polymorphic form of imatinib mesylate and a process for its preparation
EP1768982A2 (en) 2004-06-29 2007-04-04 Amgen Inc. Pyrolo [2,3-d] pyrimidines that modulate ack1 and lck activity
BRPI0514094A (pt) * 2004-08-02 2008-05-27 Osi Pharm Inc composto, composição, e, método de tratamento de distúrbio hiperproliferativo
EP1841760B1 (en) 2004-12-30 2011-08-10 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US20070059359A1 (en) * 2005-06-07 2007-03-15 Thomas Backensfeld Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
US20060275365A1 (en) * 2005-06-07 2006-12-07 Thomas Backensfeld Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
JP2008546729A (ja) * 2005-06-23 2008-12-25 ノバルティス アクチエンゲゼルシャフト イマチニブおよび血液脳関門で活性な排出ポンプの阻害剤またはデメチルイマチニブを含む組合せ剤を投与することを含んでなる固形腫瘍疾患の処置法
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
ES2378473T3 (es) * 2005-12-21 2012-04-12 Abbott Laboratories Compuestos antivirales
DE602006015861D1 (de) 2005-12-21 2010-09-09 Abbott Lab Antivirale verbindungen
BRPI0710542B8 (pt) * 2006-04-20 2021-05-25 Janssen Pharmaceutica Nv métodos para reduzir e inibir atividade cinase de c-kit em uma célula
CA2656290A1 (en) * 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
EP2094276A4 (en) 2006-12-20 2011-01-05 Abbott Lab ANTIVIRAL COMPOUNDS
US8034815B2 (en) 2007-01-11 2011-10-11 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
US20080248548A1 (en) * 2007-04-09 2008-10-09 Flynn Daniel L Modulation of protein functionalities
US20090087489A1 (en) * 2007-09-25 2009-04-02 Bella Gerber Imatinib compositions
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
EP2247596A2 (en) 2008-01-11 2010-11-10 Natco Pharma Limited Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
PL2300013T5 (pl) 2008-05-21 2025-04-28 Takeda Pharmaceutical Company Limited Pochodne fosforu jako inhibitor kinazy
WO2010006438A1 (en) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
CA2744563A1 (en) 2008-12-12 2010-06-17 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
ITRM20090578A1 (it) * 2009-11-10 2011-05-11 Noi Per Voi Onlus Nuove composizioni per il trattamento di leucemie chemioresistenti e/o di leucemie potenzialmente chemioresistenti.
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
TR201010618A2 (tr) * 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
PL394169A1 (pl) 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
AU2013223749A1 (en) 2012-02-21 2014-09-11 Sun Pharmaceutical Industries Limited Stable dosage forms of imatinib mesylate
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib
EP3257499A1 (en) 2016-06-17 2017-12-20 Vipharm S.A. Process for preparation of imatinib methanesulfonate capsules
KR20210119444A (ko) 2019-01-23 2021-10-05 노파르티스 아게 7-사이클로펜틸-2-(5-피페라진-1-일-피리딘-2-일아미노)-7h-피롤로[2,3-d]피리미딘-6-카복실산 디메틸아미드의 석신산염의 신규한 결정질 형태

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003854A1 (en) * 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US20030069174A1 (en) * 1997-03-10 2003-04-10 Ludwig Pichler Use of human alpha1-acid glycoprotein for producing a pharmaceutical preparation
CA2379035A1 (en) * 1999-07-13 2001-01-18 Shiro Akinaga Staurosporin derivatives
UA72290C2 (uk) * 1999-12-10 2005-02-15 Пфайзер Продактс Інк. СПОЛУКИ ПІРОЛО[2.3-d]ПІРИМІДИНУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ (ВАРІАНТИ), СПОСІБ ІНГІБУВАННЯ ПРОТЕЇНКІНАЗ АБО JANUS КІНАЗИ 3 (ВАРІАНТИ)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003854A1 (en) * 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use

Also Published As

Publication number Publication date
ATE432069T1 (de) 2009-06-15
HK1050993A1 (zh) 2003-07-18
AU2171901A (en) 2001-07-09
WO2001047507A3 (en) 2002-04-04
CN1414858A (zh) 2003-04-30
PT1250140E (pt) 2009-08-24
ITMI992711A1 (it) 2001-06-27
EP1250140A2 (en) 2002-10-23
AR030179A1 (es) 2003-08-13
DE60042283D1 (de) 2009-07-09
CA2394944A1 (en) 2001-07-05
BR0016817A (pt) 2002-10-01
US20090221519A1 (en) 2009-09-03
JP2003523325A (ja) 2003-08-05
ES2326307T3 (es) 2009-10-07
US20030125343A1 (en) 2003-07-03
TWI246917B (en) 2006-01-11
WO2001047507A2 (en) 2001-07-05
PE20010991A1 (es) 2001-10-23
EP1250140B1 (en) 2009-05-27
ITMI992711A0 (it) 1999-12-27
CO5271710A1 (es) 2003-04-30

Similar Documents

Publication Publication Date Title
CN1304005C (zh) 受体酪氨酸激酶抑制剂和α1－酸性糖蛋白结合化合物的联合形式
CN1197621C (zh) 促进排便的药物组合物
CN1229353C (zh) 使用喹唑啉酮类化合物的方法及组合物
CN100345830C (zh) 稠合杂芳基衍生物
CN1196685C (zh) 嘧啶衍生物
CN1496256A (zh) 用于治疗增生性疾病的埃博霉素(epo thilone)类似物和化疗剂的组合
CN1921864A (zh) 使用TGF－β抑制剂治疗神经胶质瘤
CN1419452A (zh) 协同治疗癌症的方法和组合物
CN1909908A (zh) 用于治疗蛋白激酶依赖性疾病的吡唑并[1,5－a]嘧啶－7－基－胺衍生物
CN1711089A (zh) 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合给药
US20080280900A1 (en) Bicyclic pyrimidine derivatives as calcium channel blockers
CN1501813A (zh) 视觉功能障碍改善剂
CN1278797A (zh) 氧代化合物、其制备方法和组合物及抑制parp活性的方法
CN101039673A (zh) 用于治疗涉及细胞增殖的疾病的组合
CN1774265A (zh) 神经再生药
CN1917882A (zh) 非典型抗精神病药物与促肾上腺皮质激素释放因子拮抗剂的治疗剂组合
CN1711094A (zh) Src家族非受体酪氨酸激酶抑制剂和吉西他滨的组合产品
CN1714092A (zh) 作为蛋白激酶抑制剂的噻吩并[3,2－b]吡啶－6－腈和噻吩并[2,3－b]吡啶－5－腈
CN1662537A (zh) 吡唑并[1,5－a]嘧啶衍生物和含有该衍生物的NAD(P)H氧化酶抑制剂
CN1922185A (zh) 作为激酶抑制剂的吡唑并三嗪类化合物
CN1494422A (zh) Gabaa反相激动剂与烟碱受体不完全激动剂、雌激素、选择性雌激素调节剂、或维生素e联合用于认知障碍的用途
CN1541208A (zh) 用作细胞周期蛋白依赖性激酶抑制剂的2-苯氨基-嘧啶衍生物
CN1805743A (zh) 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂
CN1263471A (zh) 含抗肿瘤药物和羟肟酸衍生物且具有抗肿瘤增强活性和/或副作用降低的药物组合物
CN1395578A (zh) 吡啶并[2,3－d]嘧啶－2,7－二胺激酶抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070314

Termination date: 20131222